Abstract
The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have